HungaryHungary

As patent cliff looms, collaborations for mAB biosimilars are born

01.10.2011

Budapest/Bad Vilbel – Hungarian drug maker Gedeon Richter plc and German STADA Arzneimittel AG have signed two separate licensing and marketing contracts to develop biosimilar versions of the monoclonal antibody drugs Rituximab and Trastuzumab.
Under the terms of the first agreement,

STADA has received non-exclusive distribution rights from Gedeon Richter for a biosimilar mimicking Roche’s blockbuster rituximab against arthritis and diverse cancers, which had European sales of around €1.15bn last year. The antibody drug copy, which is expected to hit the market at the end of 2017, will be marketed by STADA in geographical Europe and the CIS area, but not in Russia. Richter may grant one additional license to another partner in the region covered by the contract. In addition to a one digit million upfront payment, STADA will pay milestones totalling “a low double-digit million euro figure”.
Under the terms of the second contract, Richter will in-license a preclinical Trastuzumab bio­similar candidate from

STADA for a low single-digit million euro figure. STADA terminated development of the compound last year in the course of a restructuring process, and Richter said it had acquired the rights ”in order to accelerate its own ongoing development of a Trastuzumab biosimilar.” Richter says it expects clinical testing of the copycat drug to begin in two years. At that point in time, STADA will have the option to acquire a distribution license for the bio­similar, which will seek to mimic Roche’s €1.39bn blockbuster.
Experts expect the market for bio­similars to grow to US$10bn annually by 2015 as patents run out on a number of original biologicals – most of them thera­peutic antibodies.

HungaryHungary

05.03.2012

It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...

HungaryHungary

09.08.2011

Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...

HungaryHungary

09.08.2011

Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...

HungaryHungary

04.04.2011

Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...

HungaryHungary

06.02.2011

Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term...

HungaryHungary

03.11.2010

Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...

HungaryHungary

16.09.2010

Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically...

HungaryHungary

01.07.2010

Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...

HungaryHungary

01.02.2010

Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...

HungaryHungary

30.12.2009

Budapest/Zug/Edinburgh – Swiss/Hungarian antibody specialist ImmunoGenes has inked a collaboration and license agreement with the Scottish Roslin Institute to develop specialised sheep that use ImmunoGenes’ proprietary technology...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-hungary/article/as-patent-cliff-looms-collaborations-for-mab-biosimilars-are-born.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products